Management and cost of snakebite injuries at a teaching and referral hospital in Western Kenya [version 1; peer review: 2 approved, 2 approved with reservations]

Mitchel Otieno Okumu¹,², Minal Naran Patel¹, Foram Rajnkant Bhogayata¹, Francis Okumu Ochola³, Irene Awuor Olweny¹, Joshua Orungo Onono², Joseph Kangangi Gikunju⁴

¹Pharmacy, Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya
²Public Health, Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Nairobi, Nairobi, Kenya
³Pharmacology and Toxicology, Moi University, Eldoret, Kenya
⁴Medical Laboratory Science, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

Abstract

Background: Data on the cost of snakebite injuries may inform key pillars of universal health coverage including proper planning, allocation, and utility of resources. This study evaluated the injuries, management, and costs resulting from snakebites at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) in Kenya.

Methods: In total, medical records of 127 snakebite victims attending JOOTRH between January 2011 and December 2016 were purposely selected and data on the age, gender, type of residence (urban or rural), part of the body bitten, time of bite, injuries, pre-hospital first aid, time to hospital, length of stay, treatment, and costs were collected. Regression analysis was used to predict the total indirect cost of snakebite injuries and \( p \leq 0.05 \) was considered significant. Mortality and loss of income of hospitalized victims were considered as direct costs.

Results: It was found that 43 victims were 13-24 years of age, 64 were female, 94 were from rural areas, 92 were bitten on the lower limbs, 49 were bitten between 6.00 pm and midnight, 43 attempted pre-hospital first aid, and the median time to hospital was 4.5 hours. Antivenom, supportive therapy, antibiotics, antihistamines, corticosteroids, analgesics, and non-steroidal anti-inflammatory drugs were used. Cellulitis, compartment syndrome, gangrenous foot, psychiatric disorder, and death were the main complications. Most victims spent 1-5 days in hospital and the median cost of treating a snakebite was 2652 KES (~$26). Drugs, ward charges, and nursing procedures were the highest contributors to the total indirect cost. Victims hospitalized for 6-10 days and >10 days incurred 32% and 62% more costs, respectively, compared to those hospitalized for 1-5 days.
Conclusions: The longer snakebite victims are hospitalized, the higher the cost incurred. Continuous medical education on the correct management of snakebites should be encouraged to minimize complications that may increase hospital stays and costs incurred.

Keywords
snakebite, snakebite envenoming, costs of snakebite, universal health coverage, neglected tropical disease, snakebite burden, sub-Saharan Africa, management of snakebite

This article is included in the Neglected Tropical Diseases collection.
Introduction
Snakebite envenomation is a topic perhaps too little discussed on the global stage. The disease has only recently been formally re-instated to the WHO list of neglected tropical diseases after a four-year hiatus. The additional focus is welcome and has been widely anticipated by many people that deal with and understand the devastating impact of snakebite envenoming on individuals, their families, and communities in general. It is widely hoped that the reinstatement will significantly boost efforts to reduce the burden of snakebite in Asia, Africa, and Latin America where the burden is highest.

Specifying the requirements for antivenom at the local level, educating at-risk groups, improving accessibility to antivenoms, and training of healthcare personnel are the major challenges in addressing snakebites. Most of the mitigative strategies focus on ways and means of addressing these challenges. However, evaluating the cost associated with managing snakebites at the local hospital level has often been overlooked. To date, there are no studies that provide estimates for how much it may cost to treat a victim of a snakebite at the local hospital setting.

Kenya is a country with a population of about 40 million people. Access to affordable healthcare in the country has often been fraught with controversy. In a bid to provide quality healthcare to its citizens, the government of Kenya has recently adopted the big four agenda, which seeks to deliver healthcare, food security, manufacturing growth, and affordable housing. To deliver on healthcare, the government has embraced the Kenyan Health Policy, which borrows heavily from the WHO model on Universal Healthcare Coverage (UHC). The aim is to ensure that every Kenyan receives quality healthcare (promotive, preventive, curative and rehabilitative) without suffering financial strain.

There has been a huge clamor for UHC in Kenya. However, only four counties/administrative units, namely Kisumu, Isiolo, Nyeri, and Machakos, have been selected to pilot the rollout of the program. Data on the cost of treating various diseases may inform key pillars of UHC, including proper health planning, resource allocation and utility of resources. Snakebite injuries are probably one of the most hidden public health crises globally. However, in a country that is grappling with HIV/AIDS, malaria, tuberculosis and other non-communicable diseases, there is a real risk that snakebites may be further neglected in terms of policy and resource allocation. Estimating the cost of managing snakebite injuries at the local hospital level may go a long way in highlighting the gaps that require the attention of the government and other relevant stakeholders.

Methods
Ethical considerations
Permission to conduct the study was obtained from the hospital administration; ethical clearance was obtained from the Ethical Review Committee (ERC) of JOOTRH (Ref no: ERC. IB/VOL1/412). The ethical approval document is provided as Extended data (Figure S1).

Study design
This was a descriptive cross-sectional study that was carried out between July and November 2017 using data from a retrospective audit on records of acute poisoning at JOOTRH. All patients with acute poisoning due to snakebite envenoming presenting to and managed in the emergency department of JOOTRH between January 2011 and December 2016 were reviewed for inclusion. Victims transferred from health centers, dispensaries, and sub-county hospitals to JOOTRH were counted once after thorough scrutiny of the medical records to ensure there was no double reporting. The medical records had to have all the study variables of interest; age, gender, type of residence (urban or rural), part of the body bitten, time of bite, injuries, pre-hospital first aid, time to hospital, length of stay, treatment, and costs.

Any medical records that had incomplete information or did not have any of these parameters of interest were excluded from the analysis. In total, 127 medical records of snakebite victims attending the hospital between January 2011 and December 2016 were purposely selected for the study. The digital archiving of medical records at JOOTRH based on the international classification of diseases begun in January 2011 and this made it easier for us to access/trace the physical medical records, as opposed to periods before the digital archiving was in place. We therefore selected a five-year time frame from the period of inception of the digital archiving as our study period. Data on the age, gender, type of residence (urban or rural) of the victim, part of the body bitten, and the time of the bite was retrieved. Other data retrieved included the type of injuries, pre-hospital management measures, time taken to reach the hospital, length of stay at the hospital, type of treatment, and associated costs. Indirect costs included those related to registration, admission, file fees, laboratory, laundry, physiotherapy, nursing procedures, antivenom, other drugs, daily ward charges, caretaker costs, cost of non-pharmaceuticals, surgical operations on victims, and miscellaneous. The direct costs considered in this analysis were those incurred due to mortalities and loss of income by patients who were hospitalized.

Study setting
The study was carried out at JOOTRH, a referral hospital in Kisumu County. In December of 2018, the county was selected as the first of four counties to pilot UHC in Kenya. The hospital has a wide catchment area encompassing up to 10 counties (Kisumu, Siaya, Homa Bay, Migori, Kisii, Kakamega, Vihiga, Bungoma, Busia, and Nandi) within the Western Kenya region. Based on estimates from the most recent census (2009), these
counties are estimated to have a population of around 970, 000, 840,000, 750,000, 260,000, 1,150,000, 1,660,000, 550, 000, 1,600,000, 490, 000, and 750,000 people, respectively\(^7\). Curative, preventive, promotive and rehabilitative health services are provided at JOOTRH\(^8\).

**Data handling and statistical analysis**

Sociodemographic data from the pre-structured proforma were collated in MS Excel spreadsheets and analyzed using descriptive statistics. Categorical variables were presented in frequencies and percentages and qualitative variables were handled through thematic analysis. Quantitative data including costs of treatment were analyzed using descriptive statistical measures including measures of central tendency; mean, median and measures of dispersion: minimum, and maximum. Multiple linear regression was used to determine the predictors of the total indirect cost of treating snakebite (SPSS version 20.0). The total indirect cost (dependent variable) was transformed to \(\log_{10}\) and regressed against independent variables including the age, gender, and type of residence (urban or rural) of victims, location of the victims at the time of the bite, season and time of the bite, and the time taken to get to the hospital. Other independent variables were the length of hospital stay, first aid measures initiated, and part of the body bitten. \(p<0.05\) was considered significant. The direct costs considered in this analysis were those incurred due to mortalities and loss of income by patients who were hospitalized.

**Results**

The year of the bite, the type of residence (urban or rural) of victims and the seasonal distribution of snakebite in the catchment area of the hospital is summarized in Table 1\(^1\). Most bites occurred in the year 2012, with Kisumu County recording the highest number of bites. Moreover, most bites took place during the rainy season.

The majority of the victims (110/127, 86.6%) presented to hospitals within Kisumu County, 8/127 (6.3%) cases presented to hospitals in Siaya County, 4/127 (3.1%) cases presented to hospitals in Vihiga County, 2/127 (1.6%) cases presented to hospitals in Homabay County, one (0.8%) case presented to a hospital in Busia County and another one (0.8%) case presented to a hospital in Migori County. Of the 127 cases, 84 (66.1%) presented to JOOTRH as the first port of call. This was followed by nine cases (7.1%) who presented to Ahero Sub-County hospital, four cases (3.1%) who presented to the Kombewa Sub-County hospital, and another four cases (3.1%) who presented to the Nyakach Sub-County hospital (Table S1). The gender, type of residence, marital status, and age of the victims who presented to JOOTRH during the study period are summarized in Table 2. About 94/127 (74.0%) of all snakebite cases were from the rural areas and most victims were between 13 and 24 years of age.

The occupation of snakebite victims is summarized in Table 3.

The site of the bite, location of the victim at the time of the bite, and the circumstance/activity during which the snakebite occurred are shown in Table 4. Most bites were on the lower limbs, occurred outdoors, and took place while the victims were walking.

Most bites occurred between 1800 and 2359 and a majority of the victims did not attempt any form of pre-hospital measure after being bitten (Table 5).

Most of the victims took less than six hours to present to the hospital (median time was 4.5 hours). A majority reported having been bitten by what they described as a black snake and cellulitis was the most common complication (Table 6).

The symptoms of victims of snakebite who presented to JOOTRH during the study period are summarized in Table 7. The symptoms were local and systemic (neurological, hematological).

The treatment received by the victims of snakebite included the use of antivenom, supportive therapy, antimicrobial agents, anti-histamines, corticosteroids, non-steroidal anti-inflammatory agents, opioid and non-opioid analgesics and general anesthetics (Table 8).
Table 2. Gender, type of residence, marital status, and age of snakebite victims who presented to Jaramogi Oginga Odinga Teaching and Referral Hospital during the study period.

| Variable               | Frequency (n=127) |
|------------------------|-------------------|
| **Gender**             |                   |
| Male                   | 63 (49.6%)        |
| Female                 | 64 (50.4%)        |
| **Type of residence**  |                   |
| Rural                  | 94 (74.0%)        |
| Urban                  | 33 (26.0%)        |
| **Marital status**     |                   |
| Single                 | 31 (24.4%)        |
| Married                | 48 (37.8%)        |
| Divorced               | 1 (0.8%)          |
| Widowed                | 3 (2.4%)          |
| Child                  | 35 (27.6%)        |
| Not captured           | 9 (7.1%)          |
| **Age (years)**        |                   |
| 0-12                   | 31 (24.4%)        |
| 13-24                  | 43 (33.9%)        |
| 25-36                  | 25 (19.7%)        |
| 37-48                  | 13 (10.2%)        |
| 49-60                  | 9 (7.1%)          |
| 61-72                  | 4 (3.1%)          |
| 73-84                  | 2 (1.6%)          |

Table 3. Occupation of the victims of snakebite who presented to Jaramogi Oginga Odinga Teaching and Referral Hospital during the study period.

| Variable  | Frequency (n=127) |
|-----------|-------------------|
| Occupation|                   |
| Attending school | 47 (37.0%)    |
| Entrepreneur    | 20 (15.7%)     |
| Farming        | 18 (14.2%)     |
| Toddler        | 8 (6.3%)       |
| Not captured   | 7 (5.5%)       |
| Laborer        | 5 (3.9%)       |
| Unemployed     | 5 (3.9%)       |
| Artisan        | 5 (3.9%)       |
| Homemaking     | 4 (3.1%)       |
| Security       | 3 (2.4%)       |
| Hospitality    | 3 (2.4%)       |
| Teaching       | 2 (1.6%)       |

Table 4. Site of the bite, location, and activity of the victim at the time of the bite.

| Variable                          | Frequency (n=127) |
|-----------------------------------|-------------------|
| **Site of bite**                  |                   |
| Upper limbs                       | 20 (15.7%)        |
| Lower limbs                       | 92 (72.4%)        |
| Other                             | 2 (1.6%)          |
| Not specified                     | 13 (10.2%)        |
| **Location of the victim at the time of the bite** |                   |
| Indoors                           | 15 (11.8%)        |
| Outdoors                          | 71 (55.9%)        |
| Unspecified                       | 41 (32.3%)        |
| **Circumstance/activity**         |                   |
| Walking                           | 54 (42.5%)        |
| Unknown                           | 31 (24.4%)        |
| Resting/sleeping                  | 12 (9.4%)         |
| Farming                           | 12 (9.4%)         |
| Working                           | 10 (7.9%)         |
| Playing                           | 6 (4.7%)          |
| Relieving him/herself             | 2 (1.6%)          |

Of the 127 victims of snakebite, 53/127 (42%) received antivenom while 74/127 (58%) did not. Of those that received antivenom, 51 survived while two died. Among the victims who received antivenom, 44 received one vial of antivenom, six received two vials of antivenom, one received three vials of antivenom, and another two received five vials of antivenom (Table S2, Extended data)\(^9\). Among those who did not receive antivenom, 72 survived and two died.

Of the 52 victims of snakebite who survived after receiving antivenom, 15 had complications including cellulitis (n=7), compartment syndrome (n=4), gangrenous foot (n=2), a psychiatric episode (n=1), and soft tissue injury (n=1). None of the 74 victims who did not receive antivenom developed any complications.

The majority (107/127, 84%) of all victims of snakebite spent between one and five days in the hospital, 12 (9%) spent between six and 10 days, two (1.6%) spent between 11 and 15 days and another two (1.6%) spent between 16 and 20 days (Figure 1). There was one victim (0.8%) who spent between 21 and 25 days in the hospital, while another two (1.6%) victims spent between 26 and 30 days in the hospital (Figure 1).

When considered in terms of the daily minimum wage in Kenya (KES 452; ~$4 USD), victims of snakebite who spent at least five, 10 and 20 days in the hospital lost about KES 2260 (~$22), KES 4520 (~$44) and KES 9,040 (~$88) worth of wages, respectively.
Table 5. Time of bite, and pre-hospital first aid measures taken by victims who presented to Jaramogi Oginga Odinga Teaching and Referral Hospital during the study period.

| Variable                                      | Frequency (n=127) |
|-----------------------------------------------|-------------------|
| Time of bite                                  |                   |
| 06:00–11:59                                  | 22 (17.3%)        |
| 12:00–17:59                                  | 24 (18.9%)        |
| 18:00–23:59                                  | 49 (38.6%)        |
| 00:00–05:59                                  | 9 (7.1%)          |
| No data                                      | 23 (18.1%)        |
| Pre-hospital measures                        |                   |
| None                                          | 86 (67.7%)        |
| Tourniquet only                              | 14 (11.0%)        |
| Herbal medicine only                         | 10 (7.9%)         |
| Tourniquet, incisions, herbal medicine        | 9 (7.1%)          |
| Herbal medicine, incisions                   | 3 (2.4%)          |
| Incisions only                               | 2 (1.6%)          |
| Burning matchstick at the site of the bite    | 1 (0.8%)          |
| Herbal medicine, limb immobilization         | 1 (0.8%)          |
| Herbal medicine, cleaning wound with cold water | 1 (0.8%)    |
| Tourniquet, cloth impregnated with charcoal  | 1 (0.8%)          |
| Tourniquet, incisions                        | 1 (0.8%)          |
| Tourniquet, application of vaseline at the site of the bite | 1 (0.8%) |
| Cleaning the wound with potassium permanganate | 1 (0.8%)    |
| Cleaning the wound with povidone-iodine      | 1 (0.8%)          |
| Tourniquet, pouring paraffin on the site of the bite | 1 (0.8%) |

Table 6. The time taken to get to the hospital, description of offending snakes, and the complications of snakebite among victims who presented to Jaramogi Oginga Odinga Teaching and Referral Hospital during the study period.

| Variable                                      | Frequency (n=127) |
|-----------------------------------------------|-------------------|
| Time taken to get to the hospital            |                   |
| 0–6 hours                                    | 54 (42.5%)        |
| 6–12 hours                                   | 14 (11.0%)        |
| >12 hours                                    | 10 (7.9%)         |
| No data                                      | 49 (38.6%)        |
| Description of offending snakes              |                   |
| Black snake                                  | 49 (38.6%)        |
| Snake not seen                               | 44 (34.6%)        |
| Green snake                                  | 13 (10.2%)        |
| Brown snake                                  | 8 (6.3%)          |
| Brown and black snake                        | 7 (5.5%)          |
| Grey snake with white spots                  | 1 (0.8%)          |
| Red and brown spots                          | 1 (0.8%)          |
| White and brown snake                        | 1 (0.8%)          |
| White, brown, and black snake                | 1 (0.8%)          |
| White-bellied snake                          | 1 (0.8%)          |
| Yellow snake                                 | 1 (0.8%)          |
| Complications of snakebite                   |                   |
| Cellulitis                                    | 18 (69.2%)        |
| Death                                         | 4 (15.4%)         |
| Compartment syndrome                         | 4 (15.4%)         |
| Gangrene                                      | 2 (7.7%)          |
| Cellulitis and gangrene                      | 1 (3.8%)          |
| Psychiatric episode                          | 1 (3.8%)          |

Table 7. Signs and symptoms of snakebite among victims in the study area during the study period.

| Classification of the symptoms | Manifestations                                                                 |
|-------------------------------|--------------------------------------------------------------------------------|
| **Local**                     | Septicemia, tissue necrosis, gangrene, swelling, edematous swelling, edema, mild tenderness on palpation, tenderness, gradual/progressive swelling, leg ulcer, purulent discharge, pitting edema, cellulitis, shiny appearance of foot, bullae on leg, blistering (ruptured and unruptured), multiple bruising on lower limbs, tense skin with bullous eruptions, bland blistering, cold leg, fang marks with/without pruritus |
| **Systemic (Neurological)**   | Radiating/pulsating/localized/sudden onset pain, pulse awareness, paresthesia, dysphagia, numbness, blurred vision, headache, frothing at the mouth, cough, unconsciousness, pin-point pupil, dizziness, elevated body temperature, weakness, dyspnea, loss of hearing on left ear, profuse sweating, slurred speech, easy fatiguability, nausea, vomiting |
| **Systemic (hematological)**  | Slight/mild/minimal bleeding, severe/excessive bleeding, hyperpigmentation at the site of the bite, ecchymosis, erythema |
Table 8. An overview of the treatment regimen used for the management of snakebite in the study area.

| Treatment          | Description                                                                 |
|--------------------|-----------------------------------------------------------------------------|
| Antivenom          | Unspecified brands                                                          |
| Supportive therapy | Normal saline, normal saline and ringer's lactate, glucose infusion         |
| Antimicrobial agents | Floxapen IV, ceftriaxone IV, floxapen PO, metronidazole IV, benzylpenicillin IV, fluconazole PO, ampicilox PO, amoxil PO, augmentin PO, co-trimoxazole PO, gentamycin IV, metronidazole PO, cefuroxime PO, ceftazidime IV, Lincomycin IV |
| Antihistamines     | Piriton IV, piriton PO, cetirizine PO                                       |
| Corticosteroids    | Hydrocortisone IV, hydrocortisone ointment, dexamethasone IV, prednisolone PO |
| Non-steroidal anti-inflammatory drugs (NSAID’s) | Diclofenac IM, ibuprofen PO, diclofenac PO, ketorolac tromethamine PO, aspirin PO, flamchek PO (chlorzoxazone:diclofenac:paracetamol:250mg/50mg/325mg), betapyn PO(paracetamol:codeine phosphate:caffeine: doxylamine succinate:450/10/50/5), aceclofenac PO |
| Analgesics         | Non-opioid (paracetamol PO), opioid (morphine PO, betapyn PO (paracetamol:codeine phosphate:caffeine: doxylamine succinate:450/10/50/5), tramadol IV, tramadol PO, tramadol IM, flamchek(chlorzoxazone:diclofenac:paracetamol:250mg/50mg/325mg) |
| General anesthetics | Suxamethonium IV, bupivacaine IM, sodium thiopental IV, pancuronium bromide IV, neostigmine IV, atropine IV, halothane IV |
| Miscellaneous      | Lasix IV, Mupirocin ointment (Bactroban), phytojemenadione IV, lignocaine IM, Aloha PO, anti-tetanus IM, emanzen forte PO, omeprazole PO, X-tone PO, adrenaline SC, orofer PO, haloperidol PO, artane PO, aldactone PO, nifedipine PO, heavy bupivacaine IM |

IV: intravenous, PO: per oral, IM: intramuscular.
The total indirect cost of managing snakebite in the study area during the period of study was KES 568,557.72 (~$5530). Seven victims of snakebite received a waiver on the total indirect costs amounting to 91,601 KES (~$890). None of these victims had any hospital insurance cover (Table S3, Extended data)\textsuperscript{10}. The highest contributors to the total indirect cost of snakebite were drugs (KES 152,964; ~$1485), ward charges (KES 142,300 KES; ~$1380), and nursing procedures (KES 81,500; ~$790) (Figure 2).

The median cost of treating snakebite was KES 2652 (~$26; range: KES 1100-41399 or ~11-400$). The predictors of the total indirect cost of treating snakebite are summarized in Table 9. Generally, victims who spent 6–10 days and >10 days incurred 32% and 62% more costs, respectively, compared to those who spent 1–5 days.

**Discussion**

To the best of our knowledge, this is the first study that has reported on the cost of snakebites in any hospital setting. Our findings suggest that drugs (excluding antivenom), ward charges, and nursing procedures are the highest contributors to the total indirect cost of managing snakebite. When antivenom is added to the valuation, the problem of managing snakebite in a local hospital setting suddenly becomes more complex. We also report that the median cost of treating snakebite was 2652 KES (~$26). According to a recently published survey, nearly half of Kenyan households earn less than 10,000 KES (~$97) per month, while 2% have no income at all\textsuperscript{12}. What this means is that, in the event of a snakebite, around 50% of all Kenyan households would need to spend approximately 25% of their monthly income treating the condition, and another 2% would have no means of paying for the treatment. Moreover, the minimum wage in Kenya is currently KES 13,572 (~$134) per month, which translates to about KES 452 (~$4) per day\textsuperscript{13}. Hence, for a person who misses work for 10 days due to hospitalization, the lost revenue would be about KES 4,520 (~$44). In essence, this person becomes poorer as they may not be able to buy food for their family, pay rent, or pay school fees for their children. Their productivity is therefore dented, which is bound to affect their socioeconomic standing. Moreover, the four individuals in this study who died from their injuries may also have an impact on cost, as these individuals will no longer be financially available for their families who are most likely to slide into poverty.

![Figure 2. Summary of the cost of snakebite injuries in the study area.](image)
From our findings, the longer a snakebite victim was in the hospital, the more likely they were to incur higher costs. Additionally, we established that spending more than 10 days in the hospital was associated with a 62% increase in the total cost, relative to spending between one and five days in hospital. A length of stay of between six and 10 days was associated with a 32% increase in the total cost of treating the snakebite at the hospital.

The first guidelines for the prevention, diagnosis, and management of snakebite envenoming in Kenya were published in April 2019. These guidelines provide details of how snakebite envenoming should be managed at the different levels of care in Kenya, including at the rural dispensary/health center, sub-county/district hospital, and at the referral hospital level. Based on our findings, there was no evidence that the 20-minute whole blood clotting test or any urine exam, considered as standard diagnostic tests in snakebite guidelines, were done in any of these facilities. Moreover, non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac, ketorolac, aceclofenac, and ibuprofen were routinely given to victims of snakebite, despite their use being contraindicated in managing the disease. It was also evident that some of the bites had hematological effects, including slight/mild/minimal bleeding, severe/excessive bleeding, hyper-pigmentation at the site of the bite, ecchymosis, and erythema. NSAIDs interfere with the blood coagulation cascade.

| Parameter                      | Estimate | Std. error | t(106) | p (t) | Odds |
|-------------------------------|----------|------------|--------|-------|------|
| **Type of residence**         |          |            |        |       |      |
| Rural                         | -0.04    | 0.06       | -0.64  | 0.52  | 0.96 |
| First aid measure             |          |            |        |       |      |
| Did not attempt               | -0.07    | 0.05       | -1.21  | 0.23  | 0.94 |
| Gender                        |          |            |        |       |      |
| Female                       | 0.03     | 0.05       | 0.54   | 0.59  | 1.03 |
| Location of victim            |          |            |        |       |      |
| Outdoors                     | -0.09    | 0.09       | -0.95  | 0.35  | 0.92 |
| Unspecified                  | -0.19    | 1.00       | -1.88  | 0.06  | 0.83 |
| Length of stay                |          |            |        |       |      |
| 6–10 days                    | 0.28     | 0.09       | 3.24   | 0.002 | 1.32 |
| >10 days                     | 0.48     | 0.11       | 4.42   | <0.01 | 1.00 |
| Part bitten                   |          |            |        |       |      |
| Upper limbs                   | 0.00     | 0.07       | 0.05   | 0.96  | 1.00 |
| Other                        | -0.19    | 0.20       | -0.95  | 0.35  | 0.83 |
| Unspecified                  | 0.04     | 0.09       | 0.45   | 0.66  | 1.04 |
| Season                        |          |            |        |       |      |
| Wet                          | -0.10    | 0.06       | -1.73  | 0.09  | 0.91 |
| Time of bite                  |          |            |        |       |      |
| 1200–1759                    | -0.07    | 0.08       | -0.91  | 0.37  | 0.93 |
| 1800–2359                    | 0.05     | 0.07       | 0.73   | 0.47  | 1.05 |
| 0000–0559                    | 0.16     | 0.13       | 1.26   | 0.21  | 1.17 |
| No data                      | 0.02     | 0.10       | 0.26   | 0.80  | 1.03 |
| Time to hospital              |          |            |        |       |      |
| 60–239 minutes               | -0.01    | 0.21       | -0.02  | 0.98  | 1.00 |
| 240–480 minutes              | 0.13     | 0.21       | 0.61   | 0.54  | 1.14 |
| >480 minutes                 | -0.06    | 0.22       | -0.28  | 0.78  | 0.94 |
| Not captured                 | 0.02     | 0.21       | 0.09   | 0.93  | 1.02 |
and may potentiate hematological disturbances in the event of a snakebite, particularly those from snakes with hemotoxic venom\(^1\). It is interesting to note that all the victims who died had received an NSAID (intramuscular diclofenac in particular) for snakebite-associated pain.

According to the clinical notes (particularly those that had something to do with the referral chain), the unavailability of antivenom was the main reason for referring victims from the smaller facilities to either the sub-county/district hospital or to the referral hospital. At the sub-county/district hospital level, conservative management of snakebite by use of blood transfusion or fresh frozen plasma (FFP) was often not possible as the blood/FFP was seldom available at the facilities. Furthermore, sub-county/district hospitals had to refer patients to JOOTRH for an array of reasons, including the unavailability of antivenom, the lack of the pre-requisite reagents to perform clinical and laboratory examinations, and the lack of ECG/radiography services, as well as a lack of snakebite management skills.

At JOOTRH, antivenom was also not always available, and there were many cases of victims being asked to buy the antivenom from private pharmacies in the town of Kisumu. This was a challenge, especially for cases that occurred at night. Many of the private pharmacies in the area do not operate at night and most did not stock antivenom, further delaying treatment. Furthermore, based on our findings, there was no evidence that bacterial cultures were used to inform the choice of antibiotics for managing snakebite-associated infections. This observation is troubling considering the current state of antimicrobial resistance in developing countries including Kenya. The fact that very few victims were subjected to laboratory evaluation is also quite alarming. The reasons for this observation need to be elaborated.

Despite all the shortcomings in managing snakebite at JOOTRH, there were a few positives. First, based on the two cases of gangrene that were resolved successfully (after fasciotomy), it seems that the surgical team at the facility is well equipped to manage venomous snakebite-induced necrosis. Second, it was good to see that rehabilitative services were offered to some victims by the department of physiotherapy and occupational therapy. Third, the availability of psychological services to snakebite victims was also commendable. This was exemplified by the case of a 16-year-old female victim of snakebite who had a psychiatric episode secondary to the bite, who was discharged three days after presenting to JOOTRH having received antivenom, supportive care (IV fluids) and psychological counseling.

Kisumu East sub-county contributed at least four in every ten cases of snakebite at JOOTRH during the study period. The area has several wards including Central Kolwa, East Kajulu, West Kajulu, East Kolwa, and Manyatta wards\(^\text{14}\). JOOTRH is also located in Kisumu East. We therefore posit that the numbers of patients presenting to the hospital from this region may be related to the proximity of the victims to the hospital.

There were more bites during the rainy season than the dry season, in agreement with other similar studies\(^\text{15,16}\). This observation may have something to do with the fact that snakes seek dry and safe shelter whenever heavy rains disrupt their habitats\(^\text{17}\).

Our findings of more bites occurring in the rural areas, predominantly affecting the young people, mostly being inflicted on the lower limbs and occurring in the late evenings are consistent with the reports of other similar studies\(^\text{18–22}\).

The demographic that was most affected by snakebite included students and individuals partaking in outdoor activities. Moreover, most bites occurred while the victims were walking. In rural Africa, more often than not, students have to travel long distances to have access to education. We posit that these students may have been bitten in the evening hours as they walked back home from school.

The symptoms of snakebite envenoming and the description of the offending snakes are largely consistent with the type of snakes known to be in the area. These snakes are mostly of the Viperidae and Elapidae families\(^\text{6}\) and include the puff adder (\textit{Bitis arietans}), gaboon viper (\textit{Bitis gabonica}), rhinoceros viper (\textit{Bitis nasicornis}), black mamba (\textit{Dendroaspis polylepis}), Jameson’s mamba (\textit{Dendroaspis jamesoni}), the eastern forest cobra (\textit{Naja subfulva}), and the gold tree cobra (\textit{Pseudohaje goldi})\(^\text{6}\).

More than half of all the victims did not attempt any pre-hospital first aid measures. A similar number reported to the hospital within six hours of having been bitten. When taken collectively, this may suggest that the locals recognize that snakebite is a medical emergency requiring urgent medical intervention. On the other hand, the lack of initiative by the victims or their proxies in attempting any pre-hospital measure may suggest that the population is not knowledgeable on the appropriate steps to take in the event of snakebite. Where some form of pre-hospital measure was used, the measure adopted cannot be considered beneficial. Some of the measures are contraindicated and have been shown to do more harm than good\(^\text{19}\). The use of tourniquets, incisions, suction, heat, ice, alcohol, and electric shock have all been reported to be counterproductive in snakebites\(^\text{20}\). The jury may still be out on the role of herbal medicine in snakebites. Those that oppose the practice argue that seeking treatment from traditional herbal medicine practitioners often delays access to proper medical intervention and may result in complications\(^\text{21–23}\). In contrast, proponents of herbal medicine argue that the purpose of herbal medicine is not to replace antivenom, but serve an adjunctive role, particularly in managing local effects of envenomation such as necrosis, as has been reported by several authors\(^\text{26–28}\). The latter seems to be buoyed by the fact that some phytochemicals isolated from medicinal plants have shown some promising \textit{in vitro} and \textit{in vivo} neutralization capacity against phospholipase A\(_2\) and metalloproteases, which are enzymes associated with local tissue damage\(^\text{26–29}\).

It is difficult to see how other practices such as burning matches at the site of the bite, the use of a cloth impregnated with charcoal, the application of petroleum jelly at the site of the bite, the use of potassium permanganate and povidone-iodine, and pouring paraffin at the site of the bite could mitigate against snakebite envenoming. There is a need for public health...
awareness programs aimed at dissuading such harmful practices from being advanced in the management of snakebite among this population.

**Limitations**
The cost of medicines and health services in Kenya are yet to be standardized and as such the indirect costs we have provided are mere estimates and may be higher or lower in other hospital settings. Moreover, this study did not capture information on the victims of snakebite who may have died on their way to the hospital or those who sought treatment outside the hospital’s catchment area. Furthermore, owing to the retrospective nature of this study, it was not possible to capture information on other costs incurred by victims, such as the costs incurred in transporting the victims to the hospital.

**Conclusions**
Snakebite injuries contribute significantly to medical costs in the hospital setting. The longer snakebite victims stay in hospital, the higher the cost. Continuous medical education on the correct management of snakebites should be encouraged to minimize snakebite-related complications that may increase hospital stay and, consequently, the cost incurred by victims. Prospective work is needed to provide better estimates of the direct and indirect costs of snakebite injuries in the hospital setting.

**Data availability**

**Underlying data**
Figshare: Raw data on the study titled ‘management and cost of snakebite injuries at a teaching and referral hospital in Western Kenya’. https://doi.org/10.6084/m9.figshare.9642005.v2

This project contains the following underlying data:
- Snake bite injuries-working data -modified.xlsx (raw demographic, medical and cost data for each participant)

**Extended data**
Figshare: Extended data on the study titled ‘management and cost of snakebite injuries at a teaching and referral hospital in Western Kenya’. https://doi.org/10.6084/m9.figshare.9204773.v5

This project contains the following extended data:
- Figure S1: Ethical approval document from the ethical review committee of Jaramogi Oginga Odinga Teaching and Referral Hospital
- Table S1: A summary of the hospitals that referred victims of snakebite to JOOTRH during the study period
- Table S2: A summary of the utility of antivenom among victims of snakebite presenting to JOOTRH during the study period
- Table S3: A summary of the waivers received by some victims of snakebite at JOOTRH during the study period

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

**Acknowledgments**
The authors acknowledge the assistance of officers at the medical records department (Jaramogi Oginga Odinga Teaching and Referral Hospital) notably the chairman Mr. Tom Kayago Morike, and others including Mr. Shem Kojo Odero, Mr. Michael Onyango Muhoma, and Ms. Miriam Akoth Okuta. We also wish to thank the administration of the Jaramogi Oginga Odinga Teaching and Referral Hospital for all the help accorded to us in collecting the data.

**References**
1. Chippaux JP: Snakebite envenomation turns again into a neglected tropical disease! J VENOM Anim Toxins Inst Top Dis. 2017; 23: 39. PubMed Abstract | Publisher Full Text | Free Full Text
2. Kasturiratne A, Wickremasinghe AR, De Silva N, et al.: The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008; 5(11): e518. PubMed Abstract | Publisher Full Text | Free Full Text
3. Census 2009 Summary of Results Archives, Kenya National Bureau of Statistics. [cited 2019 Jul 22]. Reference Source
4. Did NHIF trade in money meant to save mothers? Daily Nation. [cited 2019 Jul 22]. Reference Source
5. Budget allocates Sh451bn for Big Four agenda. Business Daily. [cited 2019 Jul 22]. Reference Source
6. Tropical N, Program D: Guidelines for Prevention Diagnosis and Management of Snakebite Envenoming in Kenya Neglected Tropical Diseases Program Ministry of Health Government of Kenya. 2019. Reference Source
7. LAUNCH OF THE UNIVERSAL HEALTH COVERAGE PILOT. [cited 2019 Jul 18]. Reference Source
8. CDC Global Health - Kenya. [cited 2019 Jul 22]. Reference Source
9. Okumu MO, Patel MN, Bhogayata FR, et al.: Acute Poisonings at a Regional Referral Hospital in Western Kenya. Trop Med Infect Dis. 2018; 3(3): pii: E96. PubMed Abstract | Publisher Full Text | Free Full Text
10. Okumu M, Patel M, Bhogayata F, et al.: Extended data on the study titled ‘management and cost of snakebite injuries at a teaching and referral hospital in Western Kenya’. 2019. http://www.doi.org/10.6084/m9.figshare.9204773.v5
11. Okumu M, Patel M, Bhogayata F, et al.: Raw data on the study titled ‘management and cost of snakebite injuries at a teaching and referral hospital in Western Kenya’. 2019. http://www.doi.org/10.6084/m9.figshare.9642005.v2
12. Survey reveals monthly income for Kenyan households. Elections 2017. [cited 2019 Jul 18]. Reference Source
13. Kenya Minimum Wages | 2019 | Data | Chart | Calendar | Forecast | News. [cited 2019 Jul 30]. Reference Source
14. Commission E: Electoral Commission of Kenya. Statistics. 2007; 1–8.
15. Phillips C, Lipman GS, Gugelmann H, et al.: Snakebites and climate change in California, 1997-2017. Clin Toxicol (Phila). 2019; 57(3): 168–74. PubMed Abstract | Publisher Full Text

16. Rahman R, Faiz MA, Selim S, et al.: Annual incidence of snake bite in rural bangladesh. PLoS Negl Trop Dis. 2010; 4(10): e860. PubMed Abstract | Publisher Full Text | Free Full Text

17. Why Snakes Come To Your Home During Storms. Critter Ridder Texas. [cited 2019 Jul 18]. Reference Source

18. Chafiq F, El Hattimy F, Rhalem N, et al.: Snakebites notified to the poison control center of Morocco between 2009 and 2013. J Venom Anim Toxins Inci Trop Dis. 2016; 22: 8. PubMed Abstract | Publisher Full Text | Free Full Text

19. Oliveira Nda R, Sousa AC, Belmino JF, et al.: The epidemiology of envenomation via snakebite in the State of Piauí, Northeastern Brazil. Rev Soc Bras Med Trop. 2015; 48(1): 99–104. PubMed Abstract | Publisher Full Text

20. Feitosa EL, Sampaio VS, Salinas JL, et al.: Older age and time to medical assistance are associated with severity and mortality of snakebites in the Brazilian Amazon: A case-control study. PLoS One. 2015; 10(7): e0132237. PubMed Abstract | Publisher Full Text | Free Full Text

21. WHO: Prevalence of snakebite envenoming, WHO. [cited 2019 Jul 10]; 2017. Available from: Reference Source

22. Ochola FO, Okumu MO, Muchemi GM, et al.: Epidemiology of snake bites in selected areas of Kenya. Pan Afr Med J. 2018; 29: 217. PubMed Abstract | Publisher Full Text | Free Full Text

23. Boyd JJ, Agazzi G, Svajda O, et al.: Venomous snakebite in mountainous terrain: prevention and management. Wilderness Environ Med. 2007; 18(3): 190–202. PubMed Abstract | Publisher Full Text

24. Kularatne AM, Silva A, Maduwage K, et al.: Victims’ response to snakebite and socio-epidemiological factors of 1018 snakebites in a tertiary care hospital in Sri Lanka. Wilderness Environ Med. 2014; 25(1): 35–40. PubMed Abstract | Publisher Full Text

25. Michael GC, Thacher TD, Shehu Mi: The effect of pre-hospital care for venomous snake bite on outcome in Nigeria. Trans R Soc Trop Med Hyg. 2011; 105(2): 95–101. PubMed Abstract | Publisher Full Text | Free Full Text

26. Molander M, Staerk D, Marcik H, et al.: Investigation of skin permeation, ex vivo inhibition of venom-induced tissue destruction, and wound healing of African plants used against snakebites. J Ethnopharmacol. 2015; 165: 1–8. PubMed Abstract | Publisher Full Text

27. Molander M, Nielsen L, Søgaard S, et al.: Hyaluronidase, phospholipase A2 and protease inhibitory activity of plants used in traditional treatment of snakebite-induced tissue necrosis in Mali, DR Congo and South Africa. J Ethnopharmacol. 2014; 157: 171–80. PubMed Abstract | Publisher Full Text

28. Liu Y, Staerk D, Nielsen MN, et al.: High-resolution hyaluronidase inhibition profiling combined with HPLC-HRMS-SPE-NMR for identification of anti-necrosis constituents in Chinese plants used to treat snakebite. Phytochemistry. 2015; 119: 62–9. PubMed Abstract | Publisher Full Text

29. Krishnan SA, Dileepkumar R, Nair AS, et al.: Studies on neutralizing effect of Ophiopogon mungos root extract against Daboia russelii venom. J Ethnopharmacol. 2014; 151(1): 543–7. PubMed Abstract | Publisher Full Text
Oommen Oommen
Department of Computational Biology and Bioinformatics, University of Kerala, Thiruvananthapuram, Kerala, 695581, India

I have read the above manuscript with interest and found it to be a good survey followed by their conclusions. The manuscript is well written with the data available and help understand the lacunae in snake bite management in Kenya. The study included authentic data collected for 5 years from JOOTRH between 2011-2016. They have screened 127 medical records having full desired data and made the analysis. They followed international classification from medical archives to arrive at their conclusions. The snake bite still remains a neglected tropical disease in Kenya as is similar in other tropical countries. The fact that snake bite victims have to travel a long distance to avail antivenom is certainly a big draw back. Even in some cases, the antivenom is still not available in place like JOOTRH. The results of the present study should be made available to Health officials to take adequate measures for future snake bit management. Ideally local county hospitals should be empowered to reduce travel time and cost of treatment. Antivenom may be made available in referral hospitals to reduce mortality and cost of treatment especially when the average monthly income of citizen is $44. The quality of antivenom also to be improved, probably with support from UN. It is welcome to take initial traditional and dependable herbal medicines and avail antitoxin from nearest county hospitals. The authors deserve credit for their commitment and concern for snake bite cases in Kenya.

The manuscript is well written and the language is good. I recommend the manuscript for indexing in your journal and also with a request to implement the important findings of this study to reduce the snake bite deaths and sufferings of the survivors.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
No source data required

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Working on herbal products for snake bite treatment and to improve the antivenom quality.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 December 2019
https://doi.org/10.5256/f1000research.22270.r56985

© 2019 Michael G. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Godpower Chinedu Michael
Department of Family Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria

Comments

General comment:
- Thank you inviting me to review this manuscript. The title of this manuscript is apt and is of relevance in many resource-limited settings.

Specific comments:
- Introduction: this beautifully written.

- Methods: Here, I appreciate the description of the study setting and reason for the choice of the period to which medical charts were reviewed (in this case, 5 years). However, I will suggest a review of your definition of costs in the economic evaluation of snakebite injuries. Generally and broadly there are two types of costs:

  1. Direct cost: Refers to the resource consumed in providing health care interventions. It consist of:

     Direct medical cost: cost of hospital stay, outpatient visits, card/consultation fees,
drugs, labs, surgery, physiotherapy, etc

Direct non-medical cost: these resources supporting medical services such as transportation cost, caregiver costs, etc.

2. Indirect cost: this refers to cost from production losses. These include cost due to incapacity to work, disability or premature death.

○ If "complications including death" from snakebite were your outcome measures, then the nomenclature should be reworded to reflect these, instead of “direct cost” as it is presently.

○ Data handling and statistical analysis: I struggled to understand what qualitative variables were analyzed through thematic analysis. Your study was of quantitative design; for instance, no focused group discussions were held. This area needs clarification or else the statement I am referring to should be deleted.

○ The results may need to reflect the queries above.

○ Conclusion: reasonably written.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: snakebite, health economics, primary care, malaria, family medicine training

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
This is a very interesting and important subject to interrogate especially in the Sub Saharan region where snake bite is a significant public health concern even though it is a neglected one. The financial burden of snake bite injuries on the health sector is even more neglected despite the fact that it is significant. So this study is indeed a welcoming breath of fresh air so to speak.

This work is acceptable for indexing with some minor corrections/revisions. While most of the current citations were referred to the paper can be enriched by citing work which has been carried out in the region, e.g. South Africa and Zimbabwe, to emphasise the commonality of the problem in the region.

The authors could also add references from the WHO “Guidelines for the Prevention and Clinical Management of Snakebites in Africa”. Although the guidelines are not very recent, they are still the prevailing ones.

What is the age group of “child” according to the authors?

What is the relevance of marital status to snakebite injuries?

Circumstances of injury, “walking”, can this be explained further...walking where?

What is “homemaking”?

Perhaps the length of hospitalisation, the site of injury and the kind of snake can be associated to give a more vivid picture. Also the association of cause of death, snake type and injury can be elaborated.

Snake identification can be confusing and difficult. A black snake is not necessarily a black mamba. A black mamba is in fact not black! It’s black inside the mouth.

What was the cause of death of the two who died after receiving antivenom? Was it due to reaction to the antivenom or late medical attention and what was the kind of injury?

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Toxicology (including snake bite toxicology, Pharmacogenetics)

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Emergency Care in Kenya

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Comments on this article**

**Version 1**

**Reader Comment 27 Jan 2020**

**Timothy Omara**, Department of Chemistry and Biochemistry, Moi University, Uasin Gishu County, Eldoret, Kenya, Eldoret, Kenya

The introduction could be fleshed up by giving some figures. For example, as far as I know Kenya, there have been serious cases of snakebites in areas like Baringo county that was almost morphing into an epidemic.

As identified by previous groups, furnishing explicit definitions of direct and indirect costs could improve the clarity of this manuscript. Snake envenomation usually cause so many socio-economic losses, including enforced borrowing, loss of productive time etc.

In addition, some of the antivenom on the East African market appears ineffective against some potentially venomous snake venoms in the region. Could this explain, in part, some of the deaths encountered for antivenin treated victims in your study?

R. A. Harrison, G. O. Oluoch, S. Ainsworth *et al.*, “Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa,” PLoS Neglected
Tropical Diseases, vol. 11, no. 10, pp. e0005969, 2017. https://doi.org/10.1371/journal.pntd.0005969

**Competing Interests:** There is completely no conflict of interest

Reader Comment 19 Sep 2019

**Stephen Otieno**, Maseno University, Maseno Kisumu, Kenya

This is a good article that is easy to read. As the two comments above indicate it would have helped if the authors gave an explicit definition of direct and indirect costs. The study period under consideration precedes the introduction of UHC and health seeking behaviour of the population may vary depending on the availability of free services. The authors are well versed on the treatment of snakebites as per the current guidelines, it would help put things in perspective if the recommended treatment protocol was costed for comparison. Not all snakes are venomous, one cannot help but wonder what is the cost of unnecessary treatment of the harmless bites.

This is a thought provoking and revelatory paper

**Competing Interests:** None declared

Reader Comment 16 Sep 2019

**Kevin WW Rombosia**, Makerere University, Uganda

Great read that is relevant to the current discussion on UHC agenda's tenet on affordability of healthcare services.

My comments:

1. Under which UHC package does snake bite management fall? This would best come out in the introduction.

2. Help the reader by defining direct vs indirect costs as related to the study topic.

3. A brief mention of the conceptual framework would be helpful in helping determine any possible confounders of the costs related to snake bite management that are incurred by a patient.

4. There is no mention of the sample size determination considerations.

5. The wage loss is considered against a blanket daily minimum wage loss. Would it be more prudent to stratify the patients into socio-economic strata and consider the wage loss in these? Would this help in getting a more accurate estimate of the wage loss? What have other similar studies done?

6. You mention qualitative thematic assessment in your methods. I did not see how these were applied.
7. The study title is on the costs of snake bite management. However, I think, your discussion is bent more on the clinical management of snake bites.

Again, this was a good read.

Best regards

**Competing Interests:** None declared.

---

Reader Comment 11 Sep 2019

**Linda Achieng**, JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU, Kenya

1. Presenting the results in the abstract section in form of percentages rather than numerics would make it easier to comprehend the findings e.g. giving the percentage of females instead of saying 64 females.

2. In my opinion, direct costs are those incurred as a direct result of the injury such as hospitalisation, ward charges, cost of pharmaceuticals and non-pharmaceuticals and laboratory charges whilst indirect costs are those that result in loss of productivity rather than vice versa. Otherwise a very well researched and easy to read article. A very interesting read.

**Competing Interests:** No competing interests were disclosed.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com